| Diacylglycerol kinases in cancer I Mérida, P Torres-Ayuso, A Ávila-Flores, J Arranz-Nicolás, E Andrada, ... Advances in biological regulation 63, 22-31, 2017 | 68 | 2017 |
| Diacylglycerol kinase ζ controls diacylglycerol metabolism at the immunological synapse SI Gharbi, E Rincón, A Avila-Flores, P Torres-Ayuso, M Almena, ... Molecular biology of the cell 22 (22), 4406-4414, 2011 | 54 | 2011 |
| Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src P Torres-Ayuso, M Daza-Martín, J Martín-Pérez, A Ávila-Flores, I Mérida Oncotarget 5 (20), 9710, 2014 | 52 | 2014 |
| Shipping out MEK inhibitor resistance with SHP2 inhibitors P Torres-Ayuso, J Brognard Cancer discovery 8 (10), 1210-1212, 2018 | 34 | 2018 |
| Newly discovered penicillin acylase activity of aculeacin A acylase from Actinoplanes utahensis J Torres-Bacete, D Hormigo, M Stuart, M Arroyo, P Torres, MP Castillón, ... Applied and Environmental Microbiology 73 (16), 5378-81, 2007 | 34 | 2007 |
| FoxO-dependent regulation of diacylglycerol kinase α gene expression M Martínez-Moreno, J García-Liévana, D Soutar, P Torres-Ayuso, ... Molecular and Cellular Biology 32 (20), 4168-4180, 2012 | 33 | 2012 |
| Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1 P Torres-Ayuso, M Tello-Lafoz, I Mérida, A Ávila-Flores Oncogenesis 4 (8), e164-e164, 2015 | 29 | 2015 |
| TNIK is a therapeutic target in lung squamous cell carcinoma and regulates FAK activation through Merlin P Torres-Ayuso, E An, KM Nyswaner, RC Bensen, DA Ritt, SI Specht, ... Cancer discovery 11 (6), 1411-1423, 2021 | 28 | 2021 |
| Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene E Testoni, NL Stephenson, P Torres‐Ayuso, AA Marusiak, EW Trotter, ... EMBO molecular medicine 8 (2), 105-116, 2016 | 25 | 2016 |
| The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells VT Hoang, K Nyswaner, P Torres-Ayuso, J Brognard Journal of Biological Chemistry 295 (25), 8470-8479, 2020 | 23 | 2020 |
| Survival of head and neck cancer cells relies upon LZK kinase-mediated stabilization of mutant p53 ZC Edwards, EW Trotter, P Torres-Ayuso, P Chapman, HM Wood, ... Cancer research 77 (18), 4961-4972, 2017 | 22 | 2017 |
| Penicillin Acylase from Streptomyces lavendulae and Aculeacin A Acylase from Actinoplanes utahensis: Two Versatile Enzymes as Useful Tools for Quorum … R Velasco-Bucheli, D Hormigo, J Fernández-Lucas, P Torres-Ayuso, ... Catalysts 10 (7), 730, 2020 | 21 | 2020 |
| Diacylglycerol kinase malfunction in human disease and the search for specific inhibitors I Merida, J Arranz-Nicolás, P Torres-Ayuso, A Ávila-Flores Lipid Signaling in Human Diseases, 133-162, 2020 | 19 | 2020 |
| Diacylglycerol kinase alpha, from negative modulation of T cell activation to control of cancer progression I Mérida, A Avila-Flores, J García, E Merino, M Almena, P Torres-Ayuso Advances in enzyme regulation 49 (1), 174-188, 2009 | 14 | 2009 |
| A Blk–p190RhoGAP signaling module downstream of activated Gα13 functionally opposes CXCL12-stimulated RhoA activation and cell invasion RA Bartolome, M Diaz-Martinez, GP Colo, N Arellano-Sánchez, ... Cellular Signalling 26 (11), 2551-2561, 2014 | 12 | 2014 |
| Combing the cancer genome for novel kinase drivers and new therapeutic targets P Torres-Ayuso, J Brognard Cancers 11 (12), 1972, 2019 | 11 | 2019 |
| Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: A case report for a cancer of … P Torres-Ayuso, S Sahoo, G Ashton, E An, N Simms, M Galvin, HS Leong, ... NPJ Genomic Medicine 3 (1), 15, 2018 | 11 | 2018 |
| Shipping out MEK inhibitor resistance with SHP2 inhibitors. Cancer Discov. 2018; 8: 1210–1212. doi: 10.1158/2159-8290 P Torres-Ayuso, J Brognard CD-18-0915.[Abstract][CrossRef][Google Scholar], 0 | 7 | |
| A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models F Ren, A Aliper, J Chen, H Zhao, S Rao, C Kuppe, IV Ozerov, M Zhang, ... Nature Biotechnology, 1-13, 2024 | 5 | 2024 |
| Degraders: the ultimate weapon against amplified driver kinases in cancer P Torres-Ayuso, J Brognard Molecular Pharmacology 101 (4), 191-200, 2022 | 5 | 2022 |
Antonia Avila-FloresDepartment of Immunology and Oncology, National Center of Biotechnology, SpainVerified email at cnb.csic.es
